$PEN

4 stories mentioning PEN

Every FINWIRES story that references PEN, newest first.

Penumbra Gets CE Mark for Thunderbolt Stroke Device in Europe

Penumbra (PEN) has received the CE Mark in Europe for its Thunderbolt computer-assisted vacuum thrombectomy technology for acute ischemic stroke, the company said Monday.The approval expands the availability of Thunderbolt into Europe after the company received US Food and Drug Administration clearance for the device last week, it said.Thunderbolt introduces modulated aspiration technology to remove blood clots during stroke treatment, Penumbra said.Price: $319.53, Change: $+0.94, Percent Change: +0.30%

$PEN

Wire3d ago

Penumbra's Thunderbolt Device Offers Revenue Upside Not Reflected in Estimates, RBC Says

Penumbra's (PEN) Thunderbolt device positions the company as the only one in the US offering computer-assisted vacuum thrombectomy technology across both vascular and neurovascular conditions, RBC Capital Markets said.The brokerage said in a Thursday note that it was encouraged by the recent US Food and Drug Administration clearance for Thunderbolt, noting that any revenue upside from the device is not currently reflected in its estimates.RBC said Thunderbolt is the only approved computer-assisted vacuum thrombectomy device for stroke treatment in the US and could help drive a new product cycle in a stroke market that has seen softer growth in recent years."Thunderbolt could catalyze a new product cycle in a stroke market that has recently seen softer growth due to a lack of major technological shifts," the investment firm said, adding that adoption will ultimately depend on whether clinical data demonstrate a clear advantage over existing treatment approaches.RBC maintained its sector perform rating on Penumbra and a $374 price target.Price: $317.84, Change: $-0.48, Percent Change: -0.15%

$PEN

Wire38d ago

Penumbra is a 'Strong' Strategic fit for Boston Scientific, RBC Says

Penumbra (PEN) is a "strong" strategic and financial fit for Boston Scientific (BSX), which expects the deal to be accretive to its profitable growth profile, RBC Capital Markets said in Wednesday research report.Penumbra delivered an upside revenue surprise in Q1 driven by outperformance in embolization and access segments, while thrombectomy sales lagged, analysts wrote.Q1 sales were primarily attributable to higher sales volume in the US due to further market penetration of products while price remained stable, according to the note.The brokerage said it reiterated its sector perform rating on the stock and price target of $374 per share, pending the deal close in H2.Price: $324.81, Change: $+0.62, Percent Change: +0.19%

$BSX$PEN

Wire63d ago

Penumbra Says Storm-PE Trial Shows Improved Functional Outcomes With Thrombectomy Plus Anticoagulation

Penumbra (PEN) said Monday that 90-day results from the STORM-PE randomized controlled trial showed patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy, or CAVT, plus anticoagulation achieved greater functional improvement than those receiving anticoagulation alone.Patients in the CAVT plus anticoagulation arm walked farther in the six-minute walk test, averaging 479 meters compared with 368 meters and reached 94% of their predicted walking distance versus 75.2% for those on anticoagulation alone. A higher proportion of patients also reported no physical limitations based on the New York Heart Association functional class scale, at 97% versus 76%.Safety outcomes through 90 days were comparable across both groups, with no device-related mortality, no additional pulmonary embolism-related deaths beyond seven days, and no difference in symptomatic recurrence.The data were presented at the Society of Interventional Radiology Annual Scientific Meeting. Penumbra said interim Strike-PE data on long-term quality of life and functional outcomes in CAVT-treated patients will be presented at the same meeting on April 15.Price: $330.63, Change: $+0.86, Percent Change: +0.26%

$PEN